Thrombin-activatable fibrinolysis inhibitor

carboxypeptidase B2
Identifiers
Symbol	CPB2
Entrez	1361
HUGO	2300
OMIM	603101
RefSeq	NM_001872
UniProt	Q96IY4
Other data
Locus	Chr. 13 q14.11

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.

TAFI is produced by the liver.

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

WikiDoc Resources for Thrombin-activatable fibrinolysis inhibitor
Articles
Most recent articles on Thrombin-activatable fibrinolysis inhibitor Most cited articles on Thrombin-activatable fibrinolysis inhibitor Review articles on Thrombin-activatable fibrinolysis inhibitor Articles on Thrombin-activatable fibrinolysis inhibitor in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Thrombin-activatable fibrinolysis inhibitor Images of Thrombin-activatable fibrinolysis inhibitor Photos of Thrombin-activatable fibrinolysis inhibitor Podcasts & MP3s on Thrombin-activatable fibrinolysis inhibitor Videos on Thrombin-activatable fibrinolysis inhibitor
Evidence Based Medicine
Cochrane Collaboration on Thrombin-activatable fibrinolysis inhibitor Bandolier on Thrombin-activatable fibrinolysis inhibitor TRIP on Thrombin-activatable fibrinolysis inhibitor
Clinical Trials
Ongoing Trials on Thrombin-activatable fibrinolysis inhibitor at Clinical Trials.gov Trial results on Thrombin-activatable fibrinolysis inhibitor Clinical Trials on Thrombin-activatable fibrinolysis inhibitor at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Thrombin-activatable fibrinolysis inhibitor NICE Guidance on Thrombin-activatable fibrinolysis inhibitor NHS PRODIGY Guidance FDA on Thrombin-activatable fibrinolysis inhibitor CDC on Thrombin-activatable fibrinolysis inhibitor
Books
Books on Thrombin-activatable fibrinolysis inhibitor
News
Thrombin-activatable fibrinolysis inhibitor in the news Be alerted to news on Thrombin-activatable fibrinolysis inhibitor News trends on Thrombin-activatable fibrinolysis inhibitor
Commentary
Blogs on Thrombin-activatable fibrinolysis inhibitor
Definitions
Definitions of Thrombin-activatable fibrinolysis inhibitor
Patient Resources / Community
Patient resources on Thrombin-activatable fibrinolysis inhibitor Discussion groups on Thrombin-activatable fibrinolysis inhibitor Patient Handouts on Thrombin-activatable fibrinolysis inhibitor Directions to Hospitals Treating Thrombin-activatable fibrinolysis inhibitor Risk calculators and risk factors for Thrombin-activatable fibrinolysis inhibitor
Healthcare Provider Resources
Symptoms of Thrombin-activatable fibrinolysis inhibitor Causes & Risk Factors for Thrombin-activatable fibrinolysis inhibitor Diagnostic studies for Thrombin-activatable fibrinolysis inhibitor Treatment of Thrombin-activatable fibrinolysis inhibitor
Continuing Medical Education (CME)
CME Programs on Thrombin-activatable fibrinolysis inhibitor
International
Thrombin-activatable fibrinolysis inhibitor en Espanol Thrombin-activatable fibrinolysis inhibitor en Francais
Business
Thrombin-activatable fibrinolysis inhibitor in the Marketplace Patents on Thrombin-activatable fibrinolysis inhibitor
Experimental / Informatics
List of terms related to Thrombin-activatable fibrinolysis inhibitor